Tyrer P
Br J Psychiatry. 1976 Apr;128:354-60. doi: 10.1192/bjp.128.4.354.
A rational approach to the use of monoamine oxidase inhibitors (MAOIs) is outlined. Patients suitable for treatment cannot be classified adequately using conventional diagnostic labels. They include those with primary symptoms of hypochondriasis, agoraphobia and social phobias, irritability, somatic anxiety and anergia; those with primary depressed mood, guilt, ideas of reference and personality disorders seldom respond. There is great variation in the interval between the first administration of these drugs and clinical response, and this may account for the inconsistencies in published trials. The type of drug and its dose may affect rate of response, as may biochemical factors, including acetylator and monoamine oxidase status. To obtain maximum benefit, a course of therapy with MAOIs should last for several months.
本文概述了使用单胺氧化酶抑制剂（MAOIs）的合理方法。适合治疗的患者无法用传统诊断标签进行充分分类。这些患者包括具有疑病症、广场恐惧症和社交恐惧症、易怒、躯体焦虑和无力等主要症状的患者；而那些具有原发性情绪低落、内疚、牵连观念和人格障碍的患者很少有反应。这些药物首次给药与临床反应之间的间隔差异很大，这可能是已发表试验结果不一致的原因。药物类型及其剂量可能影响反应速度，生化因素（包括乙酰化状态和单胺氧化酶状态）也可能有此影响。为了获得最大益处，MAOIs治疗疗程应持续数月。
